194 related articles for article (PubMed ID: 7865318)
1. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
Temoshok LR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
[No Abstract] [Full Text] [Related]
2. Behavioral studies relevant to vaccine trial preparation: an introduction.
Turner CF; Sheon AR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S273-6. PubMed ID: 7865317
[TBL] [Abstract][Full Text] [Related]
3. Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users.
Woody GE; Metzger D; Mulvaney F
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S197-9. PubMed ID: 7865300
[No Abstract] [Full Text] [Related]
4. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.
MacQueen KM; Buchbinder S; Douglas JM; Judson FN; McKirnan DJ; Bartholow B
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314
[No Abstract] [Full Text] [Related]
5. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials.
Douglas JM; Judson FN; Parks JP; Buchbinder S; McKirnan D
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S257-60. PubMed ID: 7865313
[No Abstract] [Full Text] [Related]
6. Preparations for AIDS vaccine trials. Developing brief valid screening instruments for HIV-related sexual risk behavior among gay and bisexual men.
McKirnan DJ; Doetsch J; Vanable P; Buchbinder S; Douglas JM; Judson F
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S285-8. PubMed ID: 7865320
[TBL] [Abstract][Full Text] [Related]
7. Interest in HIV vaccines among injection drug users in Baltimore, Maryland.
Vlahov D; Astemborski J; Solomon L; Galai N; Basarab L; Nelson KE
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S265-8. PubMed ID: 7865315
[TBL] [Abstract][Full Text] [Related]
8. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
Chesney MA; Lurie P; Coates TJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
[No Abstract] [Full Text] [Related]
9. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors.
Navaline HA; Snider EC; Petro CJ; Tobin D; Metzger D; Alterman AI; Woody GE
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S281-3. PubMed ID: 7865319
[TBL] [Abstract][Full Text] [Related]
10. Overview: HIV vaccine feasibility studies.
Sheon AR
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S195-6. PubMed ID: 7865299
[No Abstract] [Full Text] [Related]
11. Feasibility and cohort development for HIV vaccine trials in Haiti.
Deschamps MM; Johnson WD; Pape JW
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S231-3. PubMed ID: 7865308
[TBL] [Abstract][Full Text] [Related]
12. Social and behavioral issues in phase III HIV preventive vaccine trials.
Grinstead OA
AIDS; 1995; 9 Suppl A():S245-50. PubMed ID: 8819592
[No Abstract] [Full Text] [Related]
13. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
Meyers K; Metzger DS; McLellan AT; Navaline H; Sheon AR; Woody GE
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):577-85. PubMed ID: 8548338
[TBL] [Abstract][Full Text] [Related]
14. HIV preventive vaccine efficacy trials in the United States: an overview of target communities' concerns.
Hodel D
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S255-6. PubMed ID: 7865312
[No Abstract] [Full Text] [Related]
15. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US.
Priddy FH; Cheng AC; Salazar LF; Frew PM
Int J STD AIDS; 2006 Feb; 17(2):99-102. PubMed ID: 16464270
[TBL] [Abstract][Full Text] [Related]
16. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
Slack CM
Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209
[No Abstract] [Full Text] [Related]
17. Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".
Snyder J; Miller CL; Gray G
Am J Bioeth; 2011 Jun; 11(6):W1-3. PubMed ID: 21678202
[No Abstract] [Full Text] [Related]
18. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein.
Luzi AM; Gallo P; Colucci A; Marcotullio S; Bellino S; Longo O; Ensoli B
AIDS Care; 2011 Aug; 23(8):939-46. PubMed ID: 21390884
[TBL] [Abstract][Full Text] [Related]
19. Lack of volunteers for vaccine.
AIDS Patient Care STDS; 1999 Sep; 13(9):572. PubMed ID: 10813047
[No Abstract] [Full Text] [Related]
20. Interest in HIV vaccines among Italian injection drug users. The Network Interregionale SERT.
Serpelloni G; Vlahov D; Mazzi M; Rezza G
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):206-7. PubMed ID: 7552488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
